Scrip: industry news and insights
Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid
23 May 2022
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news...
Roche's blockbuster cancer drug Avastin (bevacizumab) generated nearly $7bn in revenues in 2018, but Avastin's solid status on Roche's top line will be tested with the launch of the first biosimilar in the US. Allergan PLC and Amgen Inc. launched the first US biosimilar for Avastin and Roche's Herceptin (trastuzumab) on 18 July, marking the first oncology biosimilar launches in the US.
It's unclear how the commercial dynamics will play out, but Scrip looked at the commercial and development history of Avastin since its first US FDA approval in 2004 for metastatic colon cancer. Avastin was a blockbuster in its first full year on the market. It rose to become Roche's top-selling drug in 2009 before losing that status in 2012 after a breast cancer indication was withdrawn.
Scrip: industry news and insights
23 May 2022
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news...
Scrip: industry news and insights
By Kevin Grogan 23 May 2022
The French major has secured a fourth approval, in eosinophilic esophagitis, for Dupixent, while the EMA is set to make...
Scrip: industry news and insights
By Anju Ghangurde 23 May 2022
Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: